Inventor · disambiguated record
Jay P. Powers
Also filed as: POWERS JAY · POWERS JAY P · POWERS JAY PATRICK
123 granted patents·33 pending applications·1,126 citations·filing 1999–2025
99Inventor score
Top patents by PatentIndex Score
156 records- 0198US11001603B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2020·Granted May 11, 2021·13 cites·1 claims
- 0297US10035768B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Jul 31, 2018·23 cites·10 claims
- 0397US9573897B2C5AR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Feb 21, 2017·24 cites·9 claims
- 0497US6528513B2Pyrimidine derivativesTULARIK INC·Filed 2000·Granted Mar 4, 2003·192 cites·42 claims
- 0596US11633416B1Oral formulations of CD73 compoundsARCUS BIOSCIENCES INC·Filed 2021·Granted Apr 25, 2023·4 cites·24 claims
- 0696US10239912B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 26, 2019·23 cites·47 claims
- 0796US9643972B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2015·Granted May 9, 2017·15 cites·47 claims
- 0896US9598422B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2015·Granted Mar 21, 2017·21 cites·34 claims
- 0996US8906938B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2013·Granted Dec 9, 2014·28 cites·5 claims
- 1096US6835726B2Pyrimidine derivativesAMGEN INC·Filed 2003·Granted Dec 28, 2004·99 cites·12 claims
- 1196US6200977B1Pyrimidine derivativesTULARIK INC·Filed 1999·Granted Mar 13, 2001·209 cites·84 claims
- 1295US11667662B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2021·Granted Jun 6, 2023·4 cites·9 claims
- 1395US10981944B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Apr 20, 2021·11 cites·20 claims
- 1495US10660897B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2018·Granted May 26, 2020·6 cites·5 claims
- 1595US9783540B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2016·Granted Oct 10, 2017·7 cites·45 claims
- 1695US9126939B2C5AR antagonistsFAN PINGCHEN·Filed 2011·Granted Sep 8, 2015·30 cites·4 claims
- 1795US8445515B2C5aR antagonistsFAN PINGCHEN·Filed 2009·Granted May 21, 2013·38 cites·25 claims
- 1894US12168023B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Granted Dec 17, 2024·1 cites·24 claims
- 1994US11787762B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2022·Granted Oct 17, 2023·2 cites·26 claims
- 2094US11142521B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Oct 12, 2021·4 cites·6 claims
- 2194US10464934B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2017·Granted Nov 5, 2019·5 cites·13 claims
- 2294US9745268B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Aug 29, 2017·11 cites·31 claims
- 2393US11407712B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2αARCUS BIOSCIENCES INC·Filed 2021·Granted Aug 9, 2022·3 cites·15 claims
- 2493US10266492B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Apr 23, 2019·8 cites·10 claims
- 2593US10106546B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2017·Granted Oct 23, 2018·6 cites·66 claims
- 2693US7132438B2Benzimidazole derivativesAMGEN INC·Filed 2002·Granted Nov 7, 2006·62 cites·29 claims
- 2792US10399962B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Sep 3, 2019·13 cites·25 claims
- 2892US9169261B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2013·Granted Oct 27, 2015·13 cites·26 claims
- 2992US7524848B2Diaza heterocyclic amide compounds and their usesAMGEN INC·Filed 2007·Granted Apr 28, 2009·24 cites·7 claims
- 3091US11059825B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Jul 13, 2021·2 cites·11 claims
- 3191US10246462B2Chemokine receptor modulators and uses thereofFLX BIO INC·Filed 2017·Granted Apr 2, 2019·10 cites·77 claims
- 3291US8916601B2Aza-aryl 1H-pyrazol-1-YL benzene sulfonamidesCHEMOCENTRYX INC·Filed 2013·Granted Dec 23, 2014·12 cites·20 claims
- 3391US6727267B2NS5B HVC polymerase inhibitorsTULARIK INC·Filed 2001·Granted Apr 27, 2004·42 cites·4 claims
- 3490US10179787B2Chemokine receptor modulators and uses thereofFLX BIO INC·Filed 2017·Granted Jan 15, 2019·5 cites·38 claims
- 3590US9758512B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2016·Granted Sep 12, 2017·6 cites·24 claims
- 3690US7776877B2N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamidesCHEMOCENTRYX INC·Filed 2008·Granted Aug 17, 2010·11 cites·6 claims
- 3789US10759789B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2019·Granted Sep 1, 2020·2 cites·27 claims
- 3889US10533014B2Immunoregulatory agentsFLEXUS BIOSCIENCES INC·Filed 2018·Granted Jan 14, 2020·3 cites·20 claims
- 3989US10532982B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Jan 14, 2020·4 cites·1 claims
- 4089US10421748B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2018·Granted Sep 24, 2019·3 cites·43 claims
- 4188US12195447B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2021·Granted Jan 14, 2025·1 cites·2 claims
- 4288US8835419B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2012·Granted Sep 16, 2014·9 cites·30 claims
- 4387US11072597B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2019·Granted Jul 27, 2021·3 cites·14 claims
- 4487US10604526B2Chemokine receptor modulators and uses thereofRAPT THERAPEUTICS INC·Filed 2018·Granted Mar 31, 2020·2 cites·25 claims
- 4587US9750722B2Diazole amidesCHEMOCENTRYX INC·Filed 2015·Granted Sep 5, 2017·5 cites·23 claims
- 4687US9567323B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2014·Granted Feb 14, 2017·6 cites·9 claims
- 4787US2025375385A1Capsule formulationsCHEMOCENTRYX INC·Filed 2025·Application pending·0 cites
- 4886US12459967B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Nov 4, 2025·0 cites·11 claims
- 4986US12103907B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2023·Granted Oct 1, 2024·0 cites·1 claims
- 5086US11434230B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2020·Granted Sep 6, 2022·1 cites·14 claims
Showing the top 50 of 156 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jay P. Powers files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →